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Abstract
Objective: To evaluate minority variant drug resistance mutations detected by the oligonucleotide ligation assay (OLA) but
not consensus sequencing among subjects with primary HIV-1 infection.
Design/Methods: Observational, longitudinal cohort study. Consensus sequencing and OLA were performed on the first
available specimens from 99 subjects enrolled after 1996. Survival analyses, adjusted for HIV-1 RNA levels at the start of
antiretroviral (ARV) therapy, evaluated the time to virologic suppression (HIV-1 RNA,50 copies/mL) among subjects with
minority variants conferring intermediate or high-level resistance.
Results: Consensus sequencing and OLA detected resistance mutations in 5% and 27% of subjects, respectively, in
specimens obtained a median of 30 days after infection. Median time to virologic suppression was 110 (IQR 62–147) days for
63 treated subjects without detectable mutations, 84 (IQR 56–109) days for ten subjects with minority variant mutations
treated with $3 active ARVs, and 104 (IQR 60–162) days for nine subjects with minority variant mutations treated with ,3
active ARVs (p=.9). Compared to subjects without mutations, time to virologic suppression was similar for subjects with
minority variant mutations treated with $3 active ARVs (aHR 1.2, 95% CI 0.6–2.4, p=.6) and subjects with minority variant
mutations treated with ,3 active ARVs (aHR 1.0, 95% CI 0.4–2.4, p=.9). Two subjects with drug resistance and two subjects
without detectable resistance experienced virologic failure.
Conclusions: Consensus sequencing significantly underestimated the prevalence of drug resistance mutations in ARV-naı ¨ve
subjects with primary HIV-1 infection. Minority variants were not associated with impaired ARV response, possibly due to
the small sample size. It is also possible that, with highly-potent ARVs, minority variant mutations may be relevant only at
certain critical codons.
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Introduction
Transmission of drug resistant HIV-1 has been well-document-
ed following the widespread availability of antiretroviral (ARV)
therapy [1–11]. In the United States, cross-sectional surveys using
consensus sequencing estimate that 11–24% of persons acquire
drug resistant HIV-1 [8,9,12,13]. National guidelines therefore
recommend genotypic resistance testing for ARV-naı ¨ve persons at
entry into care [14].
Consensus sequencing cannot consistently detect viral variants
unless they comprise greater than 10–50% of the population [15–
20], and studies using more-sensitive assays have detected
mutations at lower concentrations (i.e. ‘‘minority variant’’
mutations) in up to half of ARV-naı ¨ve subjects [21–24]. However,
the impact of minority variants on HIV-1 disease progression and
response to ARVs remains unclear. Some studies have found
associations between minority variant mutations and poor clinical
outcomes [23–30] or that outcomes were dependent on the
specific mutant codon and ARV therapy used [23,30,31], but
others have found no association between minority variants and
treatment responses [32–34].
The oligonucleotide ligation assay (OLA) is an HIV-1 drug
resistance assay that is more sensitive than consensus sequencing
and can detect mutations at select codons when they occur in as
few as 2–5% of the viral quasi-species [35–38]. This study
evaluated the prevalence of mutations detected by OLA and the
impact of minority variants on responses to ARV therapy in a
cohort of subjects with primary HIV-1 infection.
Materials and Methods
Patient population
Characteristics of the University of Washington Primary
Infection Clinic (PIC) cohort have previously been described
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28952[39–41]. For this project, we selected a subgroup from among
201 subjects in the cohort who acquired HIV-1 after highly
active ARV therapy became widely available in 1996. We
preferentially selected subjects who 1) had enrolled in the cohort
within one month of their estimated date of HIV-1 infection
(defined as the date of onset of seroconversion symptoms or, for
asymptomatic individuals, the midpoint between dates of the last
negative and first positive HIV-1 tests), 2) had results of a pre-
treatment HIV-1 drug resistance test (consensus sequencing)
already available, and/or 3) initiated ARV therapy within six
months of study enrollment. We performed consensus sequenc-
ing and sensitive drug resistance testing to determine HIV-1
genotype on the first available (i.e. baseline) plasma and
peripheral blood mononuclear cell (PBMC) specimens that had
been collected no more than seven days after the start of ARVs.
Thirty-four subjects had consensus sequencing performed as part
of clinical research evaluations prior to our undertaking this
analysis; results of resistance testing performed specifically for
this study were not used to guide selection of ARV therapy. This
study was approved by the University of Washington Institu-
tional Review Board, and all subjects gave written consent for
participation in the cohort.
HIV-1 RNA quantification in blood plasma
Specimens collected between 1996 and 2002 were initially
tested with branched DNA (bDNA) assays with lower limits of
detection of 50 and 500 copies/mL (Chiron Corporation;
Emeryville, CA). When specimens were available, results censored
at 500 copies/mL were re-tested using an ultra-sensitive reverse
transcription polymerase chain reaction (RT-PCR) assay (Roche;
Branchburg, NJ) or an independently-validated real-time RT-
PCR amplification assay with lower limits of detection equal to 50
copies/mL [42]. Since 2002, all specimens have been evaluated by
an RT-PCR assay.
RT-PCR and PCR for genotyping of HIV-1 pol
RNA was extracted from plasma and reverse transcribed, as
previously described [35]. DNA was extracted from PBMCs using
the Puregene Cell and Tissue kit (Gentra Systems, Inc.;
Minneapolis, MN) according to manufacturers’ instructions.
Nested PCR was performed as previously described [37] with
different primers. Briefly, first-round PCR of cDNA or DNA was
carried out in a 50-ml reaction mixture containing 10-ml of cDNA
or $1 mg DNA, and second-round PCR contained 2-ml of the
first-round product. First round primers were PRA and RTA;
second round primers were PRB and RT3 [43]. If no amplicon
was produced, we used alternate primer sets NE10 and NE11. We
visualized the amplicon, a 1,193-bp DNA fragment extending
from amino acid 1 in protease to amino acid 230 in reverse
transcriptase, in a 1% agarose gel with ethidium bromide staining.
Samples with a visible band of the correct size were used for
sequencing and OLA.
Consensus sequencing
PCR amplicons were purified and sequenced as previously
described [37] using sequencing primers that were identical to
those used for second-round PCR. Sequences were analyzed with
Sequencher, version 4.2 (Gene Codes Corp; Ann Arbor, MI), and
submitted to the Stanford HIV-1 Sequence Analysis Program [44]
to identify mutations. For quality assurance, all genotypes
generated for this study were aligned with ClustalW, v1.81 and
reviewed using a neighbor-joining phylogenetic tree to monitor for
cross-contamination.
Oligonucleotide Ligation Assay (OLA)
Amplicons submitted to consensus sequencing were evaluated
by OLA for mutations in the region encoding reverse transcriptase
(K65R, K70R, L74V, M184V, T215F/Y, K103N, Y181C, and
G190A) and protease (D30N, I50V, V82S/A/T, I84V, N88D,
and L90M). Results for M41L are not included, as oligonucleotide
probes for this codon were not optimized when the laboratory
work for this project was completed. OLA was performed as
previously described [35–37]. All subjects’ samples and controls
were analyzed in duplicate. We classified samples as mutant if the
mean optical density (OD) of duplicates at 490 nm was greater
than the OD of the 5% mutant control or 2.5 times the OD of the
wild-type control. If the specimen was not classified as mutant and
the mean wild-type OD was under 50% of the wild-type control
OD, we classified the specimen as ‘‘indeterminate.’’
Statistical analysis
We used McNemar’s exact tests to compare the number of
subjects with transmitted drug resistance mutations detected by
OLA and consensus sequencing of plasma, by OLA and consensus
sequencing of PBMCs, and by OLA of plasma to OLA of PBMCs.
Multivariable regression models explored factors potentially
associated with risk of transmitted drug resistance and included
year of HIV-1 acquisition (divided into quartiles) to evaluate for
evidence of a secular trend.
We used 2-sample t-tests, non-parametric tests, and regression
analyses where appropriate to compare mean baseline (i.e. first
visit) CD4
+ T-cell count, baseline HIV-1 RNA level, and median
viral ‘‘set point’’ among subjects with minority variant mutations
and subjects without detectable transmitted drug resistance. We
estimated set point using the HIV-1 RNA level obtained closest to
150 days (between 120 and 730 days) following HIV-1 infection
from subjects who had not yet received ARV therapy [45].
We conducted time-to-event analyses using Cox proportional
hazard regression models with maximum likelihood estimation to
compare time to virologic suppression (defined as the first HIV-1
RNA below 50 copies/mL) among subjects receiving highly active
antiretroviral therapy. These analyses were adjusted for pre-
treatment HIV-1 RNA level closest to and within 30 days before
the start of ARVs. We excluded subjects from the time-to-event
analyses if they received only single or dual nucleoside reverse
transcriptase inhibitor (NRTI) therapy or if they had any
mutations detected by consensus sequencing because pre-treat-
ment resistance testing could have guided selection of ARVs. The
Stanford University HIV Drug Resistance Database (http://
hivdb.stanford.edu; accessed December 29, 2009) was used to
predict the number of active agents in regimens; an ARV agent
was considered inactive if subjects had a mutation associated with
intermediate or high-level HIV-1 drug resistance to that ARV.
Subjects were divided into three groups: 1) subjects without any
HIV-1 drug resistance mutations detected by consensus sequenc-
ing or OLA, 2) subjects with minority variant mutations treated
with ARV regimens with three or more active ARV agents, and 3)
subjects with minority variant mutations treated with ARV
regimens with fewer than three active agents. Virologic failure
was defined as: 1) failure to suppress HIV-1 RNA levels to below
50 copies/mL within 240 days after initiation of ARVs, 2) switch
of ARV agents due to a perceived inadequate response to therapy,
or 3) viral rebound to greater than 500 copies/mL on two
consecutive measurements following successful suppression of
HIV-1 RNA levels to below 50 copies/mL. All statistical analyses
were performed using Stata9 software (StataCorp LP, College
Station, TX).
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Demographics and other baseline characteristics of the 99
subjects are shown in Table 1. All subjects were men, and 98% of
subjects reported sex with men as their risk for HIV-1 acquisition.
Subjects who experienced symptoms consistent with the acute
retroviral syndrome (92%) were over-represented in this analysis
compared to the entire PIC cohort (84%). All subjects acquired
HIV-1 subtype B infection.
We performed HIV-1 drug resistance testing on plasma and
PBMC specimens that had been obtained a median of 29 (IQR
19–66) and 31 (IQR 19–66) days after HIV-1 infection; all
specimens were collected within six months of infection.
Consensus sequencing and OLA detected HIV-1 drug resistance
mutations (in either plasma or PBMCs) in 5% and 27% of 99
subjects, respectively. There was no evidence of a trend in
incidence of transmitted drug resistance over time, although
resistance was more common among subjects infected after May
2000 (31%) compared to those infected prior to this date (16%),
and we did not detect non-nucleoside reverse transcriptase
inhibitor (NNRTI) resistance among subjects infected prior to
this date.
Compared to consensus sequencing, OLA detected significantly
greater number of subjects with resistance mutations in both
plasma (p=.0005) and PBMCs (p=.002) (Table 2). OLA
performed on plasma and PBMCs detected similar numbers of
subjects with drug resistance mutations, but concordance of results
was low.
Consensus sequencing detected one subject with M184V in
PBMCs only, one subject with M41L and T215D, one subject
with T215D and L90M, and two subjects with G190A. The
mutations most commonly identified by OLA in reverse
transcriptase were M184V (n=9) and T215Y (n=5) and in
protease were I84V (n=5) and N88D (n=5). K103N was
identified in only one subject and by OLA only. With use of
OLA, detection of NRTI resistance mutations increased from 3%
to 13% of subjects, detection of NNRTI resistance mutations
increased from 2% to 8% of subjects, detection of protease
inhibitor (PI) resistance mutations increased from 1% to 13% of
subjects, and detection of multi-drug resistant HIV-1 increased
from 1% to 6% of subjects.
Compared to subjects without detectable mutations, there were
no differences in the CD4
+ T-cell counts or HIV-1 RNA levels at
presentation among subjects having at least one mutation detected
by OLA or subjects with mutations conferring resistance to
NRTIs, NNRTIs, or PIs. Among 24 subjects in this study who
remained untreated at a median of 146 days following HIV-1
infection, the median viral ‘‘set point’’ was 4.5 (IQR 3.7–4.8) log10
copies/mL among five subjects with minority variant mutations
and 4.5 (IQR 4.1–5.3) log10 copies/mL among 19 subjects with no
detectable drug resistance mutations (p=.6).
Eighty-nine (90%) of the 99 subjects initiated ARV therapy a
median of 48 (IQR 24–107, range 5–1092) days after HIV-1
infection (Table 3). Mean CD4
+ T-cell counts (498 versus 486
cells/mm
3, p=.8) and HIV-1 RNA levels (5.1 versus 4.9 log10
copies/mL, p=.5) at the start of ARV therapy did not differ
between subjects without detectable mutations and those with
minority variant mutations. Similarly, we found no association
between any class of drug resistance mutation and CD4 count or
HIV-1 RNA level at the start of ARV therapy.
The five subjects with mutations detected by consensus
sequencing and two other treated subjects without follow-up were
excluded from survival analyses. Median time to HIV-1 RNA less
than 50 copies/mL was 110 (IQR 62–147) days for 63 treated
subjects without detectable mutations, 84 (IQR 56–109) days for
ten subjects with minority variant mutations treated with three or
more active ARVs, and 104 (IQR 60–162) days for nine subjects
with minority variant mutations treated with fewer than three
active ARVs (p=.9) (Figure 1). After adjustment for HIV-1 RNA
levels at the start of ARV therapy, time to virologic suppression
was similar (aHR 1.2, 95% CI 0.6–2.4, p=.6) for subjects with
minority variant mutations treated with at least three active agents
and for subjects with minority variant drug resistance mutations
who received fewer than three active ARV agents (aHR 1.0, 95%
CI 0.4–2.4, p=.9) compared to subjects without drug resistance
mutations.
Table 1. Characteristics of study subjects with primary HIV-1 infection evaluated for drug resistance mutations.
No mutations Mutations by OLA only Mutations by CS All Subjects
n=72 n=22 n=5 n=99
Age (median, IQR) 34 (30–38) 37 (30–43) 33 (33–41) 34 (30–40) NS
Caucasian, non-Hispanic 92% 95% 100% 93% NS
Days from infection to
screening (median, IQR)
22 (13–52) 32 (24–63) 54 (34–80) 27 (15–63) p=.05
CD4
+ T-cell count at first
visit (median cells/mm
3,I Q R )
494 (386–678) 551 (394–700) 421 (396–550) 496 (392–694) NS*
HIV RNA level at first visit
(median log10 copies/mL, IQR)
5.4 (4.5–6.2) 5.1 (4.6–5.5) 5.2 (5.0–6.0) 5.2 (4.5–6.0) NS*
Median date of HIV infection (IQR) 8/01 (1/00-1/04) 4/02 (4/01-1/04) 1/02 (8/00-4/04) 11/01 (4/00-2/04) NS
Received ARV treatment 64 (89%) 20 (91%) 5 (100%) 89 (90%) NS
PI/NRTI 26 (41%) 7 (35%) 2 (40%) 35 (39%) NS
Initial NNRTI /NRTI 24 (38%) 9 (45%) 2 (40%) 35 (39%)
ARV PI/NNRTI/NRTI 13 (20%) 3 (15%) 1 (20%) 17 (19%)
regimen NRTI only 1 (2%) 1 (5%) 0 2 (2%)
OLA: oligonucleotide ligation assay; CS: consensus sequencing; IQR: interquartile range; NS: not significant at p=.05; ARV: antiretroviral; PI: protease inhibitor; NRTI:
nucleoside reverse transcriptase inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor therapy.
*differences between groups were not significant in analyses that were both unadjusted and adjusted for time from infection to the date of sampling.
doi:10.1371/journal.pone.0028952.t001
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with mutations identified by consensus sequencing, were followed
for a median of 4.4 (IQR 2.6–7.7) person-years following the start
of ARV therapy. Only four (5%) subjects experienced virologic
failure. One subject (Table 3 ID #95816) did not have resistance
testing performed prior to starting ARV therapy. After virologic
failure, G190A was identified in his baseline specimen by both
consensus sequencing and OLA. The second subject with virologic
failure (ID #26973) had no major mutations identified by
consensus sequencing. His HIV-1 RNA level decreased to 2.0
log10 copies/mL before it quickly rebounded; T215Y was detected
by only OLA in his PBMCs from baseline. Drug resistance
mutations were not identified at baseline in two other subjects who
experienced virologic failure after receiving ARV therapy for five
months and five years;
Discussion
The results described here represent one of the most
comprehensive surveys of minority variant drug resistance in
primary HIV-1 infection in terms of the number of mutations
studied. We detected drug resistance mutations in 27% of a male
cohort who acquired HIV-1 infection after 1996. Despite a high
prevalence of minority variant drug resistance mutations, this was
not associated with a difference in viral set point or in the virologic
response to ARV therapy among treated subjects.
The finding that a sensitive assay detected HIV-1 drug
resistance mutations in a greater number of subjects compared
to consensus sequencing is consistent with other studies of ARV-
naı ¨ve subjects with primary [21,32] and established HIV-1
infection [24,46]. Although the high prevalence of minority
variants in our subjects is somewhat incongruous with the
previously-held belief that sexual transmission of HIV infection
is predominantly monophyletic, more recent data have suggested
that men who have sex with men frequently acquire multiple
variants [47]. It is also possible that OLA detected variants that
had been spontaneously generated by random misincorporation of
base pairs during reverse transcription of HIV RNA. However,
although possible, it is unlikely that, without ARV selection
pressure, mutations could be generated with sufficient frequency to
reach a level detectable by OLA in nearly one quarter of our
subjects [48]. It is also conceivable that false positive results
contributed to the estimated prevalence of drug resistance in our
subjects. Although ligase binding is highly specific [49], false
positive results could have occurred due to high background in the
EIA portion of the assay for isolated specimens.
In contrast to our previous study of ARV-experienced persons
with chronic HIV-1 infection [37], OLA of PBMC DNA did not
detect a greater number of persons with mutations compared to
OLA of plasma RNA. All minority variant drug resistance
mutations detected in this study were identified in only one
component of blood (i.e. either plasma or PBMCs but not both).
These specimens had concentrations of mutant virus that were
close to the limit of detection of the assay, and thus detection in
plasma or PBMCs was likely stochastic. We suspect that the reason
the numbers of persons who had mutations detected in one
component or the other were similar was due to collection of
specimens during primary infection with insufficient time lapse for
wild-type viruses to have overgrown less fit mutants in plasma,
where virus turnover occurs more rapidly. One of the strengths of
this work is that we studied subjects close to the time of HIV
acquisition, as outgrowth of some wild-type viruses can occur very
quickly [50,51]. We also cannot exclude the possibility that
minority variants were spontaneously generated, as mentioned
above.
Similar to other studies [32–34], we found that low-level
mutations did not appear to affect the time to virologic suppression
following initiation of ARV therapy in treated subjects. In
contrast, studies of persons with established HIV-1 infection have
shown an increased risk of virologic failure associated with
minority variant drug resistance mutations [23,24,26,27,29,30],
particularly with NNRTI mutations [28–31]. The high rate of
treatment success among our subjects was similar to another
observational study of subjects with primary HIV-1 infection [52],
but as a result only 4% of subjects were observed to have virologic
failure and our study was underpowered to detect differences in
clinical outcomes. Although the median follow-up time in our
study was longer than other studies that observed higher rates of
virologic failure, it is possible we would have seen differences in
rates of virologic failure if subjects had remained on treatment and
in follow-up or if we had studied more subjects.
Another likely explanation for our failure to identify negative
consequences from minority variant mutations was the lack of
uniformity of the impact of HIV-1 drug resistance mutations
across regimens and the use of ARV therapy with a high genetic
barrier to resistance to the mutations we observed. Much prior
research on this topic has focused on NNRTI mutations, which
have a lower genetic barrier to resistance. Of the two subjects in
our cohort with NNRTI mutations who were treated with
NNRTI-based regimens, the one who had high concentrations
of mutant experienced virologic failure (ID#95816). The second
subject (ID#44378) had the Y181C mutation detected only by
Table 2. HIV-1 drug resistance in ARV-naı ¨ve subjects with primary HIV-1 infection.
2a: OLA versus consensus
sequencing of plasma
2b: OLA versus consensus
sequencing of PBMC
2c: Consensus sequencing
of plasma versus PBMC
2d: OLA of plasma
versus PBMC
p=.0005 OLA p=.002 OLA p=1.0 PBMCs p=1.0 PBMCs
2 + 2 + 2 + 2 +
sequencing 2 83 12 sequencing 2 81 13 plasma 2 94 1 plasma 2 72 11
+ 0 4 + 1 4 + 0 4 + 10 6
ARV: antiretroviral; OLA: oligonucleotide ligation assay; PBMC: peripheral blood mononuclear cells.
+=subjects with $1 mutation or mixture.
2=subjects without mutations or with indeterminate results.
Numbers represent subjects in whom HIV-1 drug resistance was/was not detected in plasma and PBMC specimens that had been obtained a median of 29 (IQR 19–66)
and 31 (IQR 19–66) days after HIV-1 infection, respectively; all specimens were collected within six months of infection. McNemar’s exact tests compare only subjects
with discordant results (indicated in bold).
doi:10.1371/journal.pone.0028952.t002
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copies/mL decrease in his HIV-1 RNA level, but he discontinued
medications after forty-four days due to rash.
It is possible that the clinical impact of minority variant drug
resistance mutations may be modified by the relative concentra-
tion of the mutant virus at specific codons [23,30,53]. In one
recent study, subjects who had NNRTI resistance mutations
detected in 1–20% of the viral population had a lower risk of
virologic failure following initiation of ARV therapy compared to
subjects who had NNRTI resistance mutations detected in greater
than 20% of the population, but both groups had a greater risk of
virologic failure compared to subjects who did not have NNRTI
resistance mutations [23]. These authors did not observe a similar
relationship between risk of virologic failure and variation in
concentrations of NRTI or PI mutations. Another recent study
suggested that the K103N mutation was associated with an
increased risk of virologic failure when these viruses were present
in amounts greater than 2000 copies/mL [54]. However, like
many previously published studies, we did not quantify the
amount of virus used for drug resistance assays and therefore
cannot report the precise concentrations of minority variants that
were detected.
Table 3. HIV-1 drug resistance detected by consensus sequencing and OLA in ARV-naı ¨ve subjects and virologic response to ARV
therapy.
Group ID
Infection
Year CS (plasma) CS (PBMC)
OLA
(plasma)
OLA
(PBMC)
VL at
ARV
start
1 Initial ARVs
#Active
ARVs
Time to
VL,50
(days) VF
95816 2000 G190A G190A G190A G190A 4.9 ABC, 3TC, EFV,
RTV-APVRABC,
3TC, NVP
4R2
2 57 yes
69234 2004 G190A G190A G190A M184V,
T215Y,
G190A
5.6 AZT, 3TC, r-LPV 1 87
3
I 43909 2002 M184V M184V 4 ABC, 3TC, EFV 2 27
56710 1999 M41L, T215D M41L, T215D T215Y
44 , 5 4.9 3TC, d4T, IDV, HU 2 176
35188 2004 T215D, L90M T215D, L90M L90M
4 L90M
4 5.4 TDF, FTC, EFV 3 216
34993 2000 V82A 4.1 ABC, 3TC, IDV, EFV 3 15
41319 2002 I84V, N88D 4.2 ABC, 3TC, EFV 3 55
19198 2003 Y181C, I84V 5.4 AZT, 3TC, r-LPV 3 56
83622 2000 M184V 5.3 ABC, 3TC, IDV, EFV 3 60
II 35057 2004 I84V 5 ABC, 3TC, EFV 3 84
18309 2003 N88D D30N 5.4 ABC, 3TC, EFV 3 85
44375 2003 N88D 4.5 ABC, 3TC, r-IDV 3 104
66121 2001 150V N88D 4.5 ABC, 3TC, EFV 3 109
28477 2005 K103N 4.3 TDF, FTC, r-LPV 3 181
50047 2004 I84V 4.8 ABC, 3TC, EFV 3 266
78056 2003 I84V 4.1 ABC, 3TC, r-IDV 2 55
97929 2001 M184V 4.5 ABC, 3TC, EFV 2 60
71670 2000 M184V, Y181C 4.5 ABC, 3TC, IDV, EFV 2 84
81563 2001 M184V 4.9 ABC, 3TC, r-IDV 2 104
III 53754 2000 M184V, N88D 4.8 3TC, d4T, NVP 2 162
49635 2001 M184V, Y181C 4.7 ABC, 3TC, r-IDV 2 165
26973 2002 T215Y 5 ABC, AZT, 3TC 2 DNS
6 yes
44378 2005 Y181C 5.9 AZT, 3TC, NVP 2 DNS
6
78882 2004 K65R, M184V,
T215Y, I50V
5.3 TDF, FTC, r-ATZ 1 DNS
6
In this table, the subset of subjects who received antiretroviral (ARV) therapy are grouped based on whether they had drug resistance detected by consensus
sequencing (Group I), drug resistance detected by OLA but who received at least three active ARV agents (Group II), or drug resistance detected by OLA who received
fewer than three active agents (Group III). ARVs are highlighted in grey if subjects had mutations conferring at least intermediate level resistance to that ARV. K70R,
L74V, T215F, and V82S/T were not detected in any treated subjects.
CS: consensus sequencing; OLA: oligonucleotide ligation assay; VL: viral load (HIV-1 RNA level); ARV: antiretroviral; VF: virologic failure; IDV: indinavir, HU: hydroxyurea,
ABC: abacavir, EFV: efavirenz, NVP: nevirapine, r-: ritonavir-boosted, LPV: lopinavir, ATZ: atazanavir; DNS: did not suppress.
1Log10 copies/mL.
2Antiretroviral medications were switched on day 5 due to side effects.
3Subject #69234 subsequently discontinued medications two months later due to adherence difficulties.
4OLA probes did not test for M41L and T215D.
5OLA on PBMC for subject 56710 yielded indeterminate results for T215Y.
6DNS: did not suppress prior to discontinuing ARVs or study censorship. Subjects #26973, 44378, and 78882 were followed for 104, 44, and 63 days, respectively, while
receiving ARVs.
doi:10.1371/journal.pone.0028952.t003
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transmitted drug resistance mutations may be further modified by
the persistence or decay in concentration of the mutant virus. In
several studies, receipt of single dose nevirapine (SD-NVP) has
been associated with poor subsequent response to NVP-based
ARV therapy when treatment was initiated within six months of
the SD-NVP [55,56]. It is plausible that the interaction between
delayed initiation of ARV therapy following SD-NVP and reduced
risk of virologic failure is mediated by decay in the concentration
of HIV-1 drug resistant variants over time. In the study by
Jourdain et al. [56], risk for virologic failure was associated with
detection of mutations by OLA at the time of initiation of ARVs
but not with detection of mutations by consensus sequencing ten
days post-partum. How the specific mutations, threshold levels,
dynamics of decay, and timing and type of ARV therapy all
interact to modify the effect of transmitted drug resistance remains
to be determined. A longitudinal study is ongoing that will
quantify minority variants over time in a greater number of
subjects with primary HIV-1 infection.
Although OLA is more sensitive than consensus sequencing,
more sensitive assays such as allele-specific PCR [57,58] and
parallel allele-specific sequencing (PASS) [59] can detect HIV-1
drug resistance mutations in as little as 0.01–1% of the viral
population if sufficient numbers of viruses are studied. Had we
used one of these assays, it is possible that we would have
estimated that the prevalence of HIV-1 drug resistance was even
greater, and we might have found a relationship between drug
resistance and virologic response to therapy. However, in our
hands, OLA and pyrosequencing produce similar results when
mutant viruses are at concentrations greater than 2% of the viral
population [60], and the clinical relevance of minority variants at
even lower concentrations is even less clear. At the highest
sensitivity, it is possible to detect and misclassify random
mutations, as some mutations were detected among HIV-infected
persons even prior to the availability of ARVs [48,61]. Advantages
of OLA include the greater specificity compared to PCR-based
methods [62], reagents anneal at relatively low temperature (37uC)
and therefore tolerate polymorphisms in the region of the probe,
OLA uses relatively less costly equipment than allele-specific PCR
and pyrosequencing, and oligonucleotides have been adapted to
non-B subtypes [63].
In conclusion, results from this study reinforce findings of others
that consensus sequencing significantly underestimates the point
prevalence and possibly the ‘‘persistence’’ of transmitted HIV-1
drug resistance mutations. However, additional data are still
needed to precisely determine the clinical impact of different drug
resistance mutations at different concentrations. If minority
variants are clinically important, use of more-sensitive assays
might aid in the selection of potent ARV regimens with greatest
chance of success. On the other hand, if minority variant drug
resistance mutations have minimal clinical impact in ARV-naı ¨ve
individuals, the detection of minority variants might lead care
providers to prescribe complex first-line ARV regimens with a
high pill burden and frequent dosing. Higher complexity of ARV
regimens could reduce patient adherence and lead to a
paradoxical increase in the prevalence of drug resistance. Given
the uncertainty regarding the clinical impact of minority variant
mutations and the fact that many people with these mutations still
have excellent responses to therapy, prospective randomized trials
that include cost-effectiveness analyses should be completed prior
to the adoption of more-sensitive assays for clinical care.
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Figure 1. Time to suppression of plasma HIV-1 RNA levels among previously ARV-naı ¨ve subjects with and without minority variant
drug resistance mutations. Figure 1: The median time to virologic suppression (HIV-1 RNA,50 copies/mL) was 110 (IQR 62–147) days for 63
treated subjects without detectable mutations (solid line), 84 (IQR 56–109) days for 10 subjects with minority variant mutations treated with $3
active ARVs (dashed line), and 104 (60–162) days for nine subjects with minority variant mutations treated with ,3 active ARVs (dotted line) (p=.9).
doi:10.1371/journal.pone.0028952.g001
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